{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T19:45:57Z","timestamp":1770493557193,"version":"3.49.0"},"reference-count":38,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2021.12883","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T07:20:19Z","timestamp":1624951219000},"source":"Crossref","is-referenced-by-count":6,"title":["<i>In\u00a0vitro<\/i> assessment of the efficiency of the PIM\u20111 kinase pharmacological inhibitor as a potential treatment for Burkitt's lymphoma"],"prefix":"10.3892","volume":"22","author":[{"given":"Mona","family":"Alsubaie","sequence":"first","affiliation":[{"name":"Cell and Gene Therapy Group, Medical Genomics Research Department, King Abdullah International Medical Research Center, Ministry of National Guard\u2011Health Affairs, Riyadh 11481, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Matou\u2011nasri","sequence":"additional","affiliation":[{"name":"Cell and Gene Therapy Group, Medical Genomics Research Department, King Abdullah International Medical Research Center, Ministry of National Guard\u2011Health Affairs, Riyadh 11481, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Aljedai","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 12372, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed\u00a0","family":"Alaskar","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh\u00a011481, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamad","family":"Al\u2011Eidi","sequence":"additional","affiliation":[{"name":"Cell and Gene Therapy Group, Medical Genomics Research Department, King Abdullah International Medical Research Center, Ministry of National Guard\u2011Health Affairs, Riyadh 11481, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Albabtain","sequence":"additional","affiliation":[{"name":"Research Department, Health\u00a0Sciences Research Center, Princess Nourah Bint Abdulrahman University, Riyadh 11564, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khawlah\u00a0\u00a0","family":"Aldilaijan","sequence":"additional","affiliation":[{"name":"Research Department, Health\u00a0Sciences Research Center, Princess Nourah Bint Abdulrahman University, Riyadh 11564, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manal","family":"Alsayegh","sequence":"additional","affiliation":[{"name":"Cell and Gene Therapy Group, Medical Genomics Research Department, King Abdullah International Medical Research Center, Ministry of National Guard\u2011Health Affairs, Riyadh 11481, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Alabdulkareem","sequence":"additional","affiliation":[{"name":"Cell and Gene Therapy Group, Medical Genomics Research Department, King Abdullah International Medical Research Center, Ministry of National Guard\u2011Health Affairs, Riyadh 11481, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"key20210727105858_b1-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13244-019-0733-7","article-title":"An update on burkitt lymphoma: A review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence","volume":"10","author":"Kalisz","year":"2019","journal-title":"Insights Imaging"},{"key":"key20210727105858_b2-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3892\/br.2015.561","article-title":"Pim-1 kinase as cancer drug target: An update","volume":"4","author":"Tursynbay","year":"2016","journal-title":"Biomed Rep"},{"key":"key20210727105858_b3-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.biocel.2004.11.005","article-title":"The serine\/threonine kinase Pim-1","volume":"37","author":"Bachmann","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"key20210727105858_b4-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-014-0095-z","article-title":"Pim kinases in hematological malignancies: Where are we now and where are we going?","volume":"7","author":"Mondello","year":"2014","journal-title":"J Hematol Oncol"},{"key":"key20210727105858_b5-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"117866","DOI":"10.1016\/j.lfs.2020.117866","article-title":"A serine\/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy","volume":"255","author":"Panchal","year":"2020","journal-title":"Life Sci"},{"key":"key20210727105858_b6-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2217\/fon.10.106","article-title":"Why target PIM1 for cancer diagnosis and treatment?","volume":"6","author":"Magnuson","year":"2010","journal-title":"Future Oncol"},{"key":"key20210727105858_b7-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2121-7-1","article-title":"Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL","volume":"7","author":"Macdonald","year":"2006","journal-title":"BMC Cell Biol"},{"key":"key20210727105858_b8-ol-0-0-12883","first-page":"167","article-title":"Pim-1 protein kinase is nuclear in Burkitt's lymphoma: Nuclear localization is necessary for its biologic effects","volume":"23","author":"Ionov","year":"2003","journal-title":"Anticancer Res"},{"key":"key20210727105858_b9-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"448","DOI":"10.18632\/oncotarget.283","article-title":"The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas","volume":"2","author":"Forshell","year":"2011","journal-title":"Oncotarget"},{"key":"key20210727105858_b10-ol-0-0-12883","first-page":"705","article-title":"Managing tumor lysis syndrome in the era of novel cancer therapies","volume":"8","author":"McBride","year":"2017","journal-title":"J Adv Pract Oncol"},{"key":"key20210727105858_b11-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"20635","DOI":"10.1074\/jbc.M709479200","article-title":"The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells","volume":"283","author":"Zemskova","year":"2008","journal-title":"J Biol Chem"},{"key":"key20210727105858_b12-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bbadis.2016.09.012","article-title":"CD95-mediated apoptosis in Burkitt's lymphoma B-cells is associated with Pim-1 down-regulation","volume":"1863","author":"Matou-Nasri","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"key20210727105858_b13-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20210727105858_b14-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1182\/blood-2003-09-3126","article-title":"Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3","volume":"103","author":"Peltola","year":"2004","journal-title":"Blood"},{"key":"key20210727105858_b15-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.febslet.2004.06.050","article-title":"Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site","volume":"571","author":"Aho","year":"2004","journal-title":"FEBS Lett"},{"key":"key20210727105858_b16-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1182\/blood-2010-12-323022","article-title":"Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia","volume":"118","author":"Chen","year":"2011","journal-title":"Blood"},{"key":"key20210727105858_b17-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: A review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol Pathol"},{"key":"key20210727105858_b18-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.ejca.2008.06.044","article-title":"Potential roles for the PIM1 kinase in human cancer-a molecular and therapeutic appraisal","volume":"44","author":"Shah","year":"2008","journal-title":"Eur J Cancer"},{"key":"key20210727105858_b19-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1158\/0008-5472.CAN-08-0634","article-title":"Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels","volume":"68","author":"Morishita","year":"2008","journal-title":"Cancer Res"},{"key":"key20210727105858_b20-ol-0-0-12883","first-page":"208","article-title":"Understanding the functional discrepancy of Pim-1 in cancer","volume":"7","author":"Ouhtit","year":"2015","journal-title":"Front Biosci (Elite Ed)"},{"key":"key20210727105858_b21-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-020-0109-y","article-title":"PIM kinase inhibition: Co-targeted therapeutic approaches in prostate cancer","volume":"5","author":"Luszczak","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"key20210727105858_b22-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.bcp.2012.09.018","article-title":"Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities","volume":"85","author":"Blanco-Aparicio","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"key20210727105858_b23-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"109","DOI":"10.15430\/JCP.2018.23.3.109","article-title":"PIM kinase as an executional target in cancer","volume":"23","author":"Zhang","year":"2018","journal-title":"J Cancer Prev"},{"key":"key20210727105858_b24-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.bmcl.2006.12.086","article-title":"Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase","volume":"17","author":"Cheney","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"key20210727105858_b25-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1995-7645(12)60132-1","article-title":"Inhibition of Pim-1 attenuates the proliferation and migration in nasopharyngeal carcinoma cells","volume":"5","author":"Jie","year":"2012","journal-title":"Asian Pac J Trop Med"},{"key":"key20210727105858_b26-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/0008-5472.CAN-07-0320","article-title":"Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity","volume":"67","author":"Pogacic","year":"2007","journal-title":"Cancer Res"},{"key":"key20210727105858_b27-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/15216540600957438","article-title":"ERK1\/2 MAP kinases in cell survival and apoptosis","volume":"58","author":"Lu","year":"2006","journal-title":"IUBMB Life"},{"key":"key20210727105858_b28-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/ijms21031102","article-title":"Targeting MAPK signaling in cancer: Drug resistance and sensitivity","volume":"21","author":"Lee","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20210727105858_b29-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1038\/onc.2011.371","article-title":"Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells","volume":"31","author":"Wang","year":"2012","journal-title":"Oncogene"},{"key":"key20210727105858_b30-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/biom8010007","article-title":"PIM kinases and their relevance to the PI3K\/Akt\/mTOR pathway in the regulation of ovarian cancer","volume":"8","author":"Aziz","year":"2018","journal-title":"Biomolecules"},{"key":"key20210727105858_b31-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.pharmthera.2015.03.001","article-title":"PIM kinase (and Akt) biology and signaling in tumors","volume":"151","author":"Warfel","year":"2015","journal-title":"Pharmacol Ther"},{"key":"key20210727105858_b32-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"37407","DOI":"10.18632\/oncotarget.9822","article-title":"Intrinsic resistance to PIM kinase inhibition in AML through p38\u03b1-mediated feedback activation of mTOR signaling","volume":"7","author":"Brunen","year":"2016","journal-title":"Oncotarget"},{"key":"key20210727105858_b33-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.3390\/ijms21103412","article-title":"Reactive oxygen species, metabolic plasticity, and drug resistance in cancer","volume":"21","author":"Bhardwaj","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20210727105858_b34-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0092-8674(00)81382-3","article-title":"Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 Not BCL-X(L)","volume":"87","author":"Zha","year":"1996","journal-title":"Cell"},{"key":"key20210727105858_b35-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1038\/sj.onc.1202741","article-title":"The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway","volume":"18","author":"Lilly","year":"1999","journal-title":"Oncogene"},{"key":"key20210727105858_b36-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"a008656","DOI":"10.1101\/cshperspect.a008656","article-title":"Caspase functions in cell death and disease","volume":"5","author":"McIlwain","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"key20210727105858_b37-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1038\/onc.2009.276","article-title":"PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis","volume":"28","author":"Gu","year":"2009","journal-title":"Oncogene"},{"key":"key20210727105858_b38-ol-0-0-12883","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/genes8040116","article-title":"The role of c-MYC in B-cell lymphomas: Diagnostic and molecular aspects","volume":"8","author":"Nguyen","year":"2017","journal-title":"Genes (Basel)"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T08:01:07Z","timestamp":1627372867000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2021.12883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6,29]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2021.12883","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"article-number":"622"}}